RemeGen Co., Ltd. — Capital/Financing Update 2021

Nov 11, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information only and is not intended to and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

==> picture [169 x 52] intentionally omitted <==

RemeGen Co., Ltd. 榮昌生物製藥（煙台）股份有限公司*

(A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 9995)

ANNOUNCEMENT ON APPROVAL OF THE PROPOSED ISSUE OF A SHARES BY THE LISTING COMMITTEE OF SCI-TECH BOARD

This announcement is made by RemeGen Co., Ltd.* 榮昌生物製藥（煙台）股份有限公司 (the “ Company ”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “ Listing Rules ”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Reference is made to the Company’s announcements dated May 10, 2021, June 21, 2021 and November 8, 2021, and circular dated May 14, 2021 containing, among other things, related matters of the proposed initial public issue of A Shares (the “ Proposed Issue of A Shares ”) and listing on the Sci-Tech Board of the Shanghai Stock Exchange (the “ Shanghai Stock Exchange ”). Unless otherwise defined, capitalized terms used in this announcement shall have the meanings as defined in the above announcements and circular.

The Board of Directors hereby announces that the 84th review meeting of the Listing Committee for the Sci-Tech Board of the Shanghai Stock Exchange in 2021 was held on November 11, 2021. In accordance with the review results of the meeting, the Proposed Issue of A Shares and listing on the Sci-Tech Board of the Shanghai Stock Exchange by the Company has been approved.

1

As the Proposed Issue of A Shares is subject to certain conditions precedent, it may or may not be completed. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the H shares of the Company. Further announcement(s) regarding the details and developments of the Proposed Issue of A Shares will be made by the Company as and when appropriate. This announcement appears for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company.

By order of the Board RemeGen Co., Ltd. Mr. Wang Weidong* Chairman and executive director

Yantai, The PRC November 11, 2021

As at the date of this announcement, the Board of the Company comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Ms. Yu Shanshan, Mr. Hao Xianjin and Dr. Ma Lan as the independent non-executive directors.

• For identification purposes

2